ARTICLE | Clinical News
Axokine: Phase II
March 5, 2001 8:00 AM UTC
REGN reported that interim follow-up data on 67 patients from a 170-patient U.S. Phase II trial of Axokine to treat obesity indicated that patients maintained their weight loss for 24 weeks after thei...